It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company.

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company. As of the ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...